Presentation is loading. Please wait.

Presentation is loading. Please wait.

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient  Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,

Published byIsabella Sartori Modified over 5 years ago

Similar presentations

Presentation on theme: "Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient  Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,"— Presentation transcript:

1 Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient  Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse, MD, PhD, Jean-Charles Soria, MD, PhD  Journal of Thoracic Oncology  Volume 10, Issue 8, Pages e72-e73 (August 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Schematic representation of HGF/c-MET pathway and HIF activity. HGF indicates hepatocyte growth factor; HRE, hypoxia response elements; HIF, hypoxia inducible factor. Journal of Thoracic Oncology  , e72-e73DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient  Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,"

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.
Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience  Debra P. Ritzwoller, PhD, Nikki.

Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience  Debra P. Ritzwoller, PhD, Nikki.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,

Two Classic Lyrics Joined by a Contemporary Tune—Environmental Pro-Carcinogen Exposure and Genetic Susceptibility in Lung Cancer Risk  Ping Yang, MD,
Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung  Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung  Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis  Matthew Koshy, MD, Renuka Malik,
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K
NA  Journal of Thoracic Oncology 

NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Hedgehog Signaling Pathway and Lung Cancer

Hedgehog Signaling Pathway and Lung Cancer
Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report  Benjamin Nisman, PhD, Hovav.

Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report  Benjamin Nisman, PhD, Hovav.

Similar presentations

Ads by Google